{"id":"NCT01412372","sponsor":"University of Utah","briefTitle":"The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study","officialTitle":"The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2019-04-22","completion":"2019-04-22","firstPosted":"2011-08-09","resultsPosted":"2020-12-31","lastUpdate":"2020-12-31"},"enrollment":61,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome"],"interventions":[{"type":"DRUG","name":"Mesalamine","otherNames":["Lialda"]},{"type":"DRUG","name":"Placebo","otherNames":["Inactive drug"]}],"arms":[{"label":"Placebo","type":"EXPERIMENTAL"},{"label":"Mesalamine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effects of long acting mesalamine (Lialda) in patients with Post-Infective Irritable Bowel Syndrome (PI-IBS). The investigators will evaluate gastrointestinal symptoms, IBS specific quality of life (IBS-QOL), and plasma cytokines before and after treatment with Lialda.","primaryOutcome":{"measure":"Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period","timeFrame":"Baseline and 8 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-4,"sd":3},{"arm":"Mesalamine","deltaMin":-13,"sd":3}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Sinusitis","light headed/dizziness","Abdominal Pain","Bloating","Increased bowel movement"]}}